{"DataElement":{"publicId":"2752642","version":"1","preferredName":"Chemotherapy Methotrexate java.lang.Boolean","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_An antimetabolite with antineoplastic and immunomodulating properties.  Methotrxate inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant properties. (NCI04)_Generic value domain for a primitive java datatype that is a Boolean value (true or false).","longName":"2752126v1.0:2178538v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2752126","version":"1","preferredName":"Chemotherapy Methotrexate","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_An antimetabolite with antineoplastic and immunomodulating properties.  Methotrxate inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant properties. (NCI04)","longName":"2404910v1.0:2591951v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2404910","version":"1","preferredName":"Chemotherapy","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)","longName":"C15632","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0094ACAF-12DD-1BCA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-09-13","modifiedBy":"ONEDATA","dateModified":"2005-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2591951","version":"1","preferredName":"Methotrexate","preferredDefinition":"An antimetabolite with antineoplastic and immunomodulating properties.  Methotrxate inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant properties. (NCI04)","longName":"C642","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2858C8FD-4163-0F92-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-31","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-01-31","modifiedBy":"ONEDATA","dateModified":"2007-01-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2222502","version":"1","preferredName":"UML DEFAULT CD","preferredDefinition":"Default Conceptual Domain for UML Loader","longName":"UML DEFAULT CD","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5E53F3B-47A4-52D1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-04-29","modifiedBy":"DWARZEL","dateModified":"2021-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4DDF39E3-80F4-46C1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-22","endDate":null,"createdBy":"UMLLOADER_LEADS","dateCreated":"2008-05-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"1/1/11 Released as part of Lymphoma Enterprise Architecture Data System (LEADS) model cleanup.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2178538","version":"1","preferredName":"java.lang.Boolean","preferredDefinition":"Generic value domain for a primitive java datatype that is a Boolean value (true or false).","longName":"java.lang.Boolean","context":"caCORE","contextVersion":"1","type":"Non-enumerated","dataType":"java.lang.Boolean","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2178532","version":"1","preferredName":"Bioinformatics","preferredDefinition":".","longName":"BIOINFORMATICS","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"CD81DD3C-8FFA-28BA-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-12-02","endDate":"2020-10-14","createdBy":"SBREXT","dateCreated":"2003-12-02","modifiedBy":"TAYLORT","dateModified":"2020-10-14","changeDescription":"10.14.20 TL changed WFS from DRAFT NEW to RETIRED ARCHIVED and added an End Date in preparation of OneData.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2320047","version":"1","preferredName":"Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation. Indicators determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)","longName":"C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FC6EF0D8-521A-6865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CD831153-DAB5-28B6-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-12-02","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-02","modifiedBy":"CURTIST","dateModified":"2007-12-05","changeDescription":"03/30/2006 - Updated defintion and datatype (previously Boolean).","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2751669","version":"1","longName":"Lymphoma Enterprise Architecture Data System (LEADS)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2813014","version":"1","longName":"edu.emory.wci.lymphoma","context":"NCIP"}]}],"AlternateNames":[{"name":"edu.emory.wci.lymphoma.Chemotherapy.methotrexate","type":"UML Qualified Attr","context":"NCIP"},{"name":"Chemotherapy:methotrexate","type":"UML Class:UML Attr","context":"NCIP"}],"ReferenceDocuments":[{"name":"Data Element Chemotherapy Methotrexate java.lang.Boolean does not have Preferred Question Text","type":"Preferred Question Text","description":"Data Element Chemotherapy Methotrexate java.lang.Boolean does not have Preferred Question Text","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4DDEB76F-2E14-2CCD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-22","endDate":null,"createdBy":"UMLLOADER_LEADS","dateCreated":"2008-05-23","modifiedBy":"CHILLIJ","dateModified":"2011-01-02","changeDescription":"1/1/11 Released as part of Lymphoma Enterprise Architecture Data System (LEADS) model cleanup","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}